Babies born to women who took the decongestant phenylephrine during their first trimester of pregnancy were eight times more likely to have endocardial cushion defect than unexposed peers, while first-trimester use of phenylpropanolamine was associated with an eightfold increased risk of ear and stomach defects. Researchers also found first-trimester use of pseudoephedrine was tied to a threefold higher risk of so-called limb reduction defects. The findings were published in the American Journal of Epidemiology.
Decongestant use in first trimester may raise risk of birth defects
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan